Skoči na glavni sadržaj

Reumatizam, Vol. 52 No. 1, 2005.

Pregledni rad

Quo vadetis coxibes?

Simeon Grazio ; Klinika za reumatologiju, fizikalnu medicinu i rehabilitaciju, Klinička bolnica “Sestre milosrdnice”, Zagreb, Hrvatska
Branimir Anić ; Zavod za kliničku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinički bolnički centar Zagreb, Zagreb, Hrvatska

Puni tekst: hrvatski pdf 472 Kb

str. 17-27

preuzimanja: 442

citiraj

Sažetak

After the withdrawall of rofecoxib from worldwide market, there is ongoing debate whether gastrointestinal safety of COX-2 inhibition compared to non-selective NSAID-s may come at the cost of increased cardiovascular events. In this paper the relevant data regarding mechanisms, effects and side effects of selected COX-2 inhibitors are presented. Possible class effect is disscused and proposed alternative therapies.

Ključne riječi

selective cyclooxigenase-2 inhibitors; non-steroidal antiinflammatory drugs; cardiovascular effect

Hrčak ID:

125959

URI

https://hrcak.srce.hr/125959

Datum izdavanja:

1.7.2005.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.599 *